ERBB2 and breast carcinoma: A clinical study with 191 breast cancer brain metastasis (BCBM) patients revealed that the overall survival for the entire cohort was less than 5 years, and that BCBM patients with the HER2-enriched tumors and TNBC had the shortest survival times of 4.3 and 3.2 years, respectively [94].